EGFR and hepatocellular carcinoma: Since inhibition of the RAS/RAF/ERK pathway is a primary antitumor mechanism of regorafenib, EGFR overexpression-mediated activation of the RAS/RAF/ERK pathway counteracts regorafenib’s inhibitory effects, resulting in acquired resistance in HCC.